Solangepras

Last updated

Solangepras
Solangepras.svg
Clinical data
Other namesSolengepras; CVN-424; CVN424
Routes of
administration 		Oral [1]
Drug class GPR6 inverse agonist
Identifiers
  • 1-[2-[4-(2,4-difluorophenoxy)piperidin-1-yl]-3-[[(3R)-oxolan-3-yl]amino]-7,8-dihydro-5H-pyrido[3,4-b]pyrazin-6-yl]ethanone
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
Formula C24H29F2N5O3
Molar mass 473.525 g·mol−1
3D model (JSmol)
  • CC(=O)N1CCC2=C(C1)N=C(C(=N2)N3CCC(CC3)OC4=C(C=C(C=C4)F)F)N[C@@H]5CCOC5
  • InChI=1S/C24H29F2N5O3/c1-15(32)31-10-6-20-21(13-31)28-23(27-17-7-11-33-14-17)24(29-20)30-8-4-18(5-9-30)34-22-3-2-16(25)12-19(22)26/h2-3,12,17-18H,4-11,13-14H2,1H3,(H,27,28)/t17-/m1/s1
  • Key:HSWVJQBEXRKOBZ-QGZVFWFLSA-N

Solangepras (INN Tooltip International Nonproprietary Name; developmental code name CVN-424), or solengepras (USAN Tooltip United States Adopted Name), is an inverse agonist of the orphan G protein-coupled receptor 6 (GPR6) which is under development for the treatment of Parkinson's disease. [1] [2] [3] [4] It is a small molecule and is taken by mouth. [1] [4] Solangepras produces hyperlocomotion and reverses haloperidol-induced catalepsy in rodents. [4] It is being developed by Cerevance. [1] [2] As of October 2024, solangepras is in phase 3 clinical trials. [1] [2]

References

  1. 1 2 3 4 5 "Solengepras". AdisInsight. 21 October 2024. Retrieved 25 February 2025.
  2. 1 2 3 "Delving into the Latest Updates on CVN-424 with Synapse". Synapse. 5 February 2025. Retrieved 25 February 2025.
  3. ↑ Gros P, Garcia LA, Fox SH (2025). "Experimental Therapeutics in Parkinson's Disease". Neurologic Clinics. doi:10.1016/j.ncl.2024.12.013.
  4. 1 2 3 Brice NL, Schiffer HH, Monenschein H, Mulligan VJ, Page K, Powell J, et al. (June 2021). "Development of CVN424: A Selective and Novel GPR6 Inverse Agonist Effective in Models of Parkinson Disease". The Journal of Pharmacology and Experimental Therapeutics. 377 (3): 407–416. doi:10.1124/jpet.120.000438. PMID   33795395.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.